The Long COVID Treatment Trial – Tirzepatide (LoCITT-T) is now open for enrollment for people with Long COVID in all states but Hawaii (shipping timelines), DC, and PR: https://t.co/K7yjhCfV3N

LoCITT-T trial was covered by Wired today: https://t.co/HE4mCQoy3g My comments include: "For the long Covid population...if you’re requiring people to come into a clinic, you’re systematically excluding the most severely affected folks who are housebound or bedbound."

A new site is enrolling for the #LongCovid ADDRESS-LC trial on bezisterim: Mount Sinai (NY)! Bezisterim is an investigational drug that has been studied in neurological disorders, including Alzheimer’s. Find a site near you: https://t.co/yS2GiXjCfV

Our randomized, placebo-controlled trial of tirzepatide (Zepbound) for #LongCovid has already enrolled >500 participants of 1000 planned in less than 2 weeks! https://t.co/GdUULj1Nmw

The faster trials enroll, the faster trials get results! If you’re interested in enrolling in a #LongCovid trial from home, see if you’re eligible below!!

"Join a fully remote clinical research study for Long COVID (U.S. residents only) The first intervention we are studying is tirzepatide, also known as ZepboundⓇ, a GLP-1 inhibitor that has shown promise in treating many illnesses."

Progress, Potential, and Possibilities: Dr. Julia Moore Vogel - Scripps Research - Visionary, Patient-Centric Health Research For All '..Vogel..Assistant Professor & Senior Program Director at Scripps Research..including The Long COVID Treatment Trial..' https://t.co/ebmNEPOblb

There are LoCITT-T participants across 46 states & DC! We currently do not have participants from: North Dakota South Dakota Mississippi Puerto Rico Can you spread the word to anyone with LC there (or in any other, generally underrepresented community): https://t.co/K7yjhCfV3N

Many Long COVID trials have reported negative results in 2024 and 2025. In our Comment for @TheLancetInfDis we argue that inadequate outcome measures might have played a role. (1/12)

Thank you to all who attended today's LoCITT-T webinar! We received over 100 questions (plus the ~50 that came in earlier) 😅 We're writing up answers to all the q's & will send that plus the recording & transcript within a week. More info at: https://t.co/K7yjhCfV3N

Coverage today @sdut https://t.co/EkO19S2yVu

Thanks to @thesicktimes team for all their work to make this op-ed this read and look so good

For more info and to enroll check out our website: https://t.co/K7yjhCfnef And/or attend our webinar tomorrow (11/5); registration is required: https://t.co/yGdX7xmLxY

Reminder - the Long COVID Treatment Trial - Tirzepatide (LoCITT-T) is open in 49 US states (all but Hawaii), DC, & PR. More info & eligibility survey here: https://t.co/K7yjhCfnef We're hosting a webinar with Q&A on 11/5, register here: https://t.co/yGdX7xmLxY

If you have brain fog & fatigue attributed to a COVID infection, the ADDRESS-LC clinical trial for Bezisterim is still enrolling! And enrollment is now open to people living with #LongCovid for over 2 years! There are 19+ trial sites across the US:

We desperately need trials to be remote, to collect data on housebound and bedbound people. Nobody understands this better than people with Long COVID and @julialmv’s trial looks absolutely amazing https://t.co/9ffOvoqGhG

Our #LongCovid clinical trial was launched today! @scrippsresearch @ScrippsRTI @julialmv https://t.co/Rob04O6nEb

San Diego Union-Tribune: "Can a weight loss and diabetes drug treat long COVID?" 'New Scripps Research trial will explore the effects of Lilly's GLP-1 drug on reducing the symptoms of the debilitating disease' https://t.co/1tXfyTGKsf

To learn more, register for our webinar on 11/5: https://t.co/yGdX7xnjnw Read the op-ed I wrote about this study & the need for at-home trials in The Sick TImes: https://t.co/8JQ2f3kvTq Read our press release: https://t.co/tAviO79Dix grateful & hopeful, JMV 16/16

my wonderful colleagues who conquered all the setbacks we encountered (especially @EricTopol who I am co-leading the trial with), our knowledgeable data safety monitoring board members, & most of all the participants who decide to spend their precious energy on this trial. 15/16